Whether RLFTF gets an approval will be dependent on how much they manipulated the data to achieve stat sig on end points. HGEN should get EUA with no problem. Which is a good sign for Cytodyn since leronlimab downregulates GM-CSF through downregulation of NF-kb.

HGEN didn't get stat sig on mortality, RLFTF did on only a subset of patients. With a properly set up and run trial we should be able to achieve that but disregarding the FDA and bumping the number of patients to 300 would help.